SURF - Surface Oncology, Inc.
After hours:
Chart Events
Slow Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.7436 |
| Open | 0.7300 |
| Bid | 0.7810 x 1200 |
| Ask | 0.8340 x 1800 |
| Day's Range | 0.7200 - 0.8342 |
| 52 Week Range | 0.5550 - 2.1500 |
| Volume | |
| Avg. Volume | 211,372 |
| Market Cap | 48.889M |
| Beta (5Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6300 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
Fair Value
Related Research
GlobeNewswireSurface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding into the third quarter of 2024 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fir
- GlobeNewswire
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models –CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (
- GlobeNewswire
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114, the company’s fully human, afucosylated anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, 2023, in Orlando, Fl. Details on the p
Simply Wall St.Surface Oncology Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
Surface Oncology ( NASDAQ:SURF ) Full Year 2022 Results Key Financial Results Revenue: US$30.0m (up by US$27.3m from FY...
- GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into the third quarter of 2024 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor micro
GlobeNewswireSurface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a Novel Immuno-Oncology (IO) panel discussion at the Cowen 43rd Annual Health Care Conference taking place at the Marriott Copley Place in Boston, MA. The panel discussion will be held on Monday, March 6, 2023
- GlobeNewswire
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on Thursday, February 9, 2023, at 1:35 p.m. ET. A live audio webcast of the session may be accessed by visiting the Events page
- Simply Wall St.
Shareholders in Surface Oncology (NASDAQ:SURF) are in the red if they invested a year ago
Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders should be happy to see the share price up 25% in the last month...
ZacksTG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
GlobeNewswireVaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery PlatformROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that its licensee, Surface Oncology (NASDAQ: SURF, “Surface”) dosed the first patient in its Phase 1/2 clinical study inve
- GlobeNewswire
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the first patient has b
- GlobeNewswire
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Data further support SRF388 and SRF114 clinical development programsCAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of two posters at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston. The posters feature new non-clinical data for both SRF388 and for SRF114 and will be presented
- Simply Wall St.
Analysts Just Made A Significant Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
Celebrations may be in order for Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders, with the analysts delivering a...
BenzingaSurface Oncology Discontinues Work On One Phase 2 Cancer Program, Lays Off 20% Workforce
Surface Oncology Inc (NASDAQ: SURF) observed confirmed partial responses from SRF388 monotherapy data in non-small cell lung cancer (NSCLC) patients. The partial responses were observed in patients treated at or above the recommended Phase 2 dose (22% ORR (2/9)), which includes 100% (2/2) of patients with squamous NSCLC. Additionally, a patient with adenocarcinoma has experienced durable disease stabilization, ongoing for more than 56 weeks. Surface has initiated a single-arm Phase 2 study evalu
- GlobeNewswire
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year – – Company focusing resources on advancement of SRF388 and SRF114, extending cash runway into Q2 2024 – – Surface reports third quarter 2022 financial results – – Management to host conference call to discuss SRF388 data and other corporate updates today at 8:30 a.m. ET – CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surfac
- GlobeNewswire
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study elucidates how SRF388 binds to IL-27 to prevent interaction with the IL-27 receptor, inhibiting the cytokine’s signaling activity –– Findings support the ongoing clinical investigation of SRF388 – FLANDERS, Belgium and CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- VIB, Flanders’ leading life sciences institute, and Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company de
- GlobeNewswire
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition - - Findings support the ongoing clinical investigation of SRF388 in multiple tumor types - CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the c
- GlobeNewswire
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section
- GlobeNewswire
Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 2:30 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Med
- Simply Wall St.
Analysts Have Just Cut Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Estimates By 11%
The analysts covering Surface Oncology, Inc. ( NASDAQ:SURF ) delivered a dose of negativity to shareholders today, by...
- Simply Wall St.
How Much Of Surface Oncology, Inc. (NASDAQ:SURF) Do Institutions Own?
If you want to know who really controls Surface Oncology, Inc. ( NASDAQ:SURF ), then you'll have to look at the makeup...
- GlobeNewswire
Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022
– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization – – Interim SRF617 clinical data anticipated in the fourth quarter of 2022 – – Multiple clinical readouts anticipated in 1H 2023, including initial safety and efficacy data from SRF388 open-label, lead-in to randomized Phase 2 study in first-line hepatocellular carcinoma (HCC) – – Cash sufficient to fund operations in
- GlobeNewswire
Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a virtual panel discussion entitled, “IOs Wide Open - Opportunity and Challenges in Immuno-Oncology” at the 2022 Wedbush PacGrow Healthcare Conference. The panel discussion will take place on Tuesday, August 9
- Simply Wall St.
Strong week for Surface Oncology (NASDAQ:SURF) shareholders doesn't alleviate pain of one-year loss
This week we saw the Surface Oncology, Inc. ( NASDAQ:SURF ) share price climb by 18%. But that hardly compensates for...
- GlobeNewswire
Surface Oncology Appoints Carsten Brunn to Board of Directors
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company’s board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. “I am thrilled to welcome Carsten to the Surface Oncology board